Rocket Pharma shares rise after FDA approval for childhood disorder therapy

• Kresladi is a one-time gene therapy that collects a patient's blood stem cells, genetically corrects the faulty gene, and reinfuses them back into the patient
• The accelerated FDA approval was based on a trial showing 100% survival at 12 months post-infusion with no treatment-related serious side effects and sharply reduced serious infections
• Analysts view the approval as strategically important for de-risking Rocket's overall gene therapy platform, though Kresladi's commercial potential is limited and will likely see only a 'minimum viable launch strategy'

Summary

Rocket Pharmaceuticals received FDA approval on March 27 for Kresladi, a gene therapy treating severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare childhood disorder affecting white blood cell function. The company's shares rose following the announcement.

Key Details:

Kresladi is the first FDA-approved treatment specifically for LAD-I, a condition where patients' white blood cells cannot properly reach infection sites, leaving them vulnerable to serious infections. Approximately 75% of untreated patients die before age two without stem cell transplants.

The therapy works as a one-time treatment by collecting patients' blood stem cells, genetically correcting the faulty gene, and reinfusing the modified cells. The FDA granted accelerated approval based on surrogate endpoints measuring improved immune cell function.

Clinical Data:

An early-to-mid-stage trial demonstrated 100% survival at 12 months post-infusion, with no treatment-related serious side effects and significantly reduced serious infections.

Market Implications:

Jefferies analyst Andrew Tsai noted the approval "de-risks overall gene therapy platform" for Rocket Pharmaceuticals, though Kresladi's commercial potential remains limited due to the rare disease indication. The company is expected to pursue a "minimum viable launch strategy."

The approval occurred under Vinay Prasad, FDA's outgoing head of biologics, who acknowledged the agency "continues to exercise significant regulatory flexibilities" for rare-disease therapies, despite his previous skepticism toward surrogate endpoints.

This milestone validates Rocket's gene therapy platform, potentially supporting future product development in the rare disease space.